Switch theme
Sign up to access all valuation multiples
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
1999
28
LTM Revenue $9.9M
Last FY EBITDA -$20.3M
-$4.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
SCYNEXIS has a last 12-month revenue (LTM) of $9.9M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, SCYNEXIS achieved revenue of $3.7M and an EBITDA of -$20.3M.
SCYNEXIS expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SCYNEXIS valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $9.9M | XXX | $3.7M | XXX | XXX | XXX |
| Gross Profit | $9.9M | XXX | $3.7M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 100% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$20.3M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -542% | XXX | XXX | XXX |
| EBIT | -$30.6M | XXX | -$37.1M | XXX | XXX | XXX |
| EBIT Margin | -308% | XXX | -991% | XXX | XXX | XXX |
| Net Profit | -$21.0M | XXX | -$21.3M | XXX | XXX | XXX |
| Net Margin | -211% | XXX | -568% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, SCYNEXIS's stock price is $1.
SCYNEXIS has current market cap of $34.1M, and EV of -$4.0M.
See SCYNEXIS trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$4.0M | $34.1M | XXX | XXX | XXX | XXX | $-0.40 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, SCYNEXIS has market cap of $34.1M and EV of -$4.0M.
SCYNEXIS's trades at -1.1x EV/Revenue multiple, and 0.2x EV/EBITDA.
Equity research analysts estimate SCYNEXIS's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SCYNEXIS has a P/E ratio of -1.6x.
See valuation multiples for SCYNEXIS and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $34.1M | XXX | $34.1M | XXX | XXX | XXX |
| EV (current) | -$4.0M | XXX | -$4.0M | XXX | XXX | XXX |
| EV/Revenue | -0.4x | XXX | -1.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBIT | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/Gross Profit | -0.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.6x | XXX | -1.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSCYNEXIS's last 12 month revenue growth is 282%
SCYNEXIS's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.5M for the same period.
SCYNEXIS's rule of 40 is 333% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
SCYNEXIS's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for SCYNEXIS and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 282% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -542% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 333% | XXX | -260% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 705% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1091% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SCYNEXIS acquired XXX companies to date.
Last acquisition by SCYNEXIS was XXXXXXXX, XXXXX XXXXX XXXXXX . SCYNEXIS acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was SCYNEXIS founded? | SCYNEXIS was founded in 1999. |
| Where is SCYNEXIS headquartered? | SCYNEXIS is headquartered in United States of America. |
| How many employees does SCYNEXIS have? | As of today, SCYNEXIS has 28 employees. |
| Who is the CEO of SCYNEXIS? | SCYNEXIS's CEO is Dr. David Angulo, M.D.. |
| Is SCYNEXIS publicy listed? | Yes, SCYNEXIS is a public company listed on NAS. |
| What is the stock symbol of SCYNEXIS? | SCYNEXIS trades under SCYX ticker. |
| When did SCYNEXIS go public? | SCYNEXIS went public in 2014. |
| Who are competitors of SCYNEXIS? | Similar companies to SCYNEXIS include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of SCYNEXIS? | SCYNEXIS's current market cap is $34.1M |
| What is the current revenue of SCYNEXIS? | SCYNEXIS's last 12 months revenue is $9.9M. |
| What is the current revenue growth of SCYNEXIS? | SCYNEXIS revenue growth (NTM/LTM) is 282%. |
| What is the current EV/Revenue multiple of SCYNEXIS? | Current revenue multiple of SCYNEXIS is -0.4x. |
| Is SCYNEXIS profitable? | Yes, SCYNEXIS is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
